Bibliography
- Andriole GL, Bruchovsky N, Chung LWK, Dihydrotestosterone and the prostate: the scientific rationale for 5 alpha-reducatase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004;172:1399-403
- Berry S.J., Coffey D.S., Walsh P.C., Ewing L.L. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9
- McConell JD, Bruskewitz R, Walsh P, The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. NEJM 1998;338:557-63
- Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=152945#cclass
- Andriole G. Overview of pivotal studies for prostate cancer risk reduction, past and present. Journal of Urology 2009;73(Supp 5A):36-43
- Iehle C, Radvanyi F, Diez de Medina SG, Differences in steroid 5 α-reductase iso-enzymes expression between normal and pathological human prostate tissue. Journal of Steroid Biochemistry and Molecular Biology 1999;68:189-195
- Andriole GL, Guess HA, Epstein JI, Treatment with finasteride preserves the usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blinded, placebo-controlled. Urology 1998;52(2):195
- Gormley GJ, Stoner E, Bruskewitz R, The effect of finasteride in men with benign prostatic hyperplasia. NEJM 1992;327:1185-91
- Roeherborn CG, Boyle P, Nickel JC, Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60(3):434-41
- Nickel JC, Gilling P, Tammela T, Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). Br J Urol Int 2011;108:388-94
- Roehrborn CG, Siami P, Barkin J, The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123-31
- Thompson IM, Goodman PJ, Tangen CM, The influence of finasteride on the development of prostate cancer. NEJM 2003;349:215-24
- Andriole GL, Bostwick DG, Brawley OW, Effect of dutasteride on the risk of prostate cancer. NEJM 2010;362:1192-202
- Walsh P. Correspondence: Dutasteride and prostate cancer. NEJM 2010;363:793-6
- Food and Drug Administration. Briefing information and slides presented at the December 1, 2010, meeting of the Oncologic Drugs Advisory Committee. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm195226.htm
- Theoret MR, Ning YM, Zhang JJ, The risks and benefits of 5 alpha-reductase inhibitors for prostate cancer prevention. NEJM 2011;365:97-9
- Fleshner N, Lucia MS, Melich IM, Effect of duatasteride on prostate cancer progression and cancer diagnosis on rebiopsy in the REDEEM active surveillance study. ASCO abstract 2011
- Limonta P, Marelli MM, Moretti RM, LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001;10(4):709
- Danila DC, Morris MJ, de Bono JS, Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010;28:1496-501
- Stanbrough M, Bubley G, Ross K, Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25
- Taplin ME, Meredith MR, Ko YJ, Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res 2009;15(22):7099-105